

Cover Story
Conversation with The Cancer LetterFree
After a decade of near-absence from the US market, the AstraZeneca drug Iressa (gefitinib) is back.
In Brief


Drugs & Targets
Trending Stories
- Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on - Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
Center directors are strategizing for likely FDA approval of GRAIL’s Galleri











